AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8622066 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine and Etoposide plus Azacitidine (250 mg/m2/d on days 4 to 50)
Number of subjects: 167
Study 8622066 — intervention group
Group type: COMPARATOR
Intervention: Control group (Amsacrine and Etoposide without Azacitidine)
Number of subjects: 167
Study 1473880 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid (800 mg)
Number of subjects: 24
Study 1473880 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered acetylsalicylic acid (500 mg)
Number of subjects: 24
Study 6378851 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + S (preoperative irradiation to the mediastinum followed by surgery)
Number of subjects: 33
Study 6378851 — intervention group
Group type: COMPARATOR
Intervention: SO (surgery only)
Number of subjects: 33
Study 31888712 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐IPT (internet-based interpersonal psychotherapy)
Number of subjects: 160
Study 31888712 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care (control)
Number of subjects: 160
Study 31888712 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐IPT
Number of subjects: 160
Study 28926676 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise arm (n=43)
Number of subjects: 87
Study 28926676 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n=44)
Number of subjects: 87
Study 27465756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 1019
Study 27465756 — intervention group
Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 1019
Study 25422827 — intervention group
Group type: EXPERIMENTAL
Intervention: Way Milano implants
Number of subjects: 64
Study 25422827 — intervention group
Group type: COMPARATOR
Intervention: Kentron implants
Number of subjects: 64
Study 22326828 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratarsal triamcinolone acetonide (TA) injection
Number of subjects: 20
Study 22326828 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone ointment
Number of subjects: 20
Study 20012616 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1650
Study 17587715 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IL-10 level (>= 30 pg/ml)
Number of subjects: 250
Study 17587715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum IL-10 level (<30 pg/ml)
Number of subjects: 250
Study 17587715 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy and at-risk subjects)
Number of subjects: 250
Study 10767816 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVE treatment (24 sessions of proprioceptive exercises, relaxation, and behavioral support)
Number of subjects: 76
Study 10767816 — intervention group
Group type: EXPERIMENTAL
Intervention: HOME treatment (neck lecture and two sessions of practical training for home exercises)
Number of subjects: 76
Study 10767816 — intervention group
Group type: COMPARATOR
Intervention: CONTROL treatment (lecture regarding care of the neck with a recommendation to exercise)
Number of subjects: 76
Study 9351730 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide measures of residual flow using (99m)Tc sestamibi
Number of subjects: 77
Study 9351730 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic flow index (sum of antegrade and collateral flow grades)
Number of subjects: 77
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous human surfactant substitution at site 2
Number of subjects: 200
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oxygen requirement during first three neonatal days
Number of subjects: 200
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mean airway pressure during second and third day
Number of subjects: 200
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PaCO2 during first two neonatal days
Number of subjects: 200
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: No ligation of ductus arteriosus
Number of subjects: 200
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluid intake during the first three days
Number of subjects: 200
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low colloid intake during the first two days of life
Number of subjects: 200
Study 8441558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean airway pressure to oxygen requirement ratio
Number of subjects: 200
Study 3530586 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 22
Study 3530586 — intervention group
Group type: COMPARATOR
Intervention: Triazolam 0.25 mg
Number of subjects: 22
Study 31497883 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Therapy Inventory of Change (STIC) feedback system (ROM condition)
Number of subjects: 328
Study 31497883 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU condition)
Number of subjects: 328
Study 29505460 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Internet Use Program (8 training sessions over 3 months)
Number of subjects: 84
Study 29505460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 84
Study 26661065 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy behaviors and weight-loss intervention
Number of subjects: 0
Study 26661065 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 24643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened patients for stroke rehabilitation trial
Number of subjects: 571
Study 24643406 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially eligible patients
Number of subjects: 571
Study 23155977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine group (intravenous ketamine 0.15 mg/kg pre-induction)
Number of subjects: 84
Study 23155977 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (normal saline)
Number of subjects: 84
Study 23155977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine group
Number of subjects: 84
Study 23155977 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 84
Study 23155977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 20724131 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 356
Study 20724131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 18069036 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate 150mg for 3 months
Number of subjects: 350
Study 18069036 — intervention group
Group type: COMPARATOR
Intervention: Weekly oral alendronate 70mg for 12 weeks
Number of subjects: 350
Study 16411527 — intervention group
Group type: EXPERIMENTAL
Intervention: icodextrin
Number of subjects: 40
Study 16411527 — intervention group
Group type: COMPARATOR
Intervention: standard glucose solutions (1.36%)
Number of subjects: 40
Study 12842163 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 12842163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0
Study 12842163 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal elderly controls)
Number of subjects: 0
Study 10379186 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP ventilation (ASPmax and PEA1/2)
Number of subjects: 20
Study 10379186 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSmax and PS1/2)
Number of subjects: 20
Study 8806116 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of osteophytes (skyline view)
Number of subjects: 250
Study 8806116 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of osteophytes (anteroposterior view)
Number of subjects: 250
Study 8806116 — intervention group
Group type: COMPARATOR
Intervention: Joint space narrowing (all views)
Number of subjects: 250
Study 8806116 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of osteophytes (all views)
Number of subjects: 250
Study 8806116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain in the last year
Number of subjects: 250
Study 2059395 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 to 8 mg/day)
Number of subjects: 75
Study 2059395 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (37.5 to 75 mg/day)
Number of subjects: 75
Study 2059395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 30861219 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance and Impact Training (HiRIT)
Number of subjects: 86
Study 30861219 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 86
Study 27692493 — intervention group
Group type: EXPERIMENTAL
Intervention: High benefits (higher mortality reduction)
Number of subjects: 218
Study 27692493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low benefits (lower mortality reduction)
Number of subjects: 218
Study 27692493 — intervention group
Group type: EXPERIMENTAL
Intervention: Low benefit-high barrier condition
Number of subjects: 218
Study 27692493 — intervention group
Group type: EXPERIMENTAL
Intervention: High benefit-low barrier condition
Number of subjects: 218
Study 25875779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 25875779 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg T enanthate
Number of subjects: 71
Study 25875779 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 mg T enanthate
Number of subjects: 71
Study 25875779 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg T enanthate
Number of subjects: 71
Study 25875779 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg T enanthate
Number of subjects: 71
Study 23597036 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 100
Study 23597036 — intervention group
Group type: COMPARATOR
Intervention: Care‐As‐Usual (CAU)
Number of subjects: 100
Study 23597036 — intervention group
Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 100
Study 23597036 — intervention group
Group type: COMPARATOR
Intervention: CAU
Number of subjects: 100
Study 21306209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 1130
Study 21306209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon up to 16 mg nightly
Number of subjects: 1130
Study 21306209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130
Study 19820286 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadodiamide (Omniscan; GE Healthcare)
Number of subjects: 162
Study 19820286 — intervention group
Group type: COMPARATOR
Intervention: Non-contrasted MRI (Control)
Number of subjects: 162
Study 18543495 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflor yellow powder injection (150 mg/d) + Benazepril (10 mg/day)
Number of subjects: 76
Study 18543495 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (10 mg/day)
Number of subjects: 76
Study 16046306 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxyntomodulin
Number of subjects: 0
Study 16046306 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 12014437 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 331
Study 12014437 — intervention group
Group type: COMPARATOR
Intervention: Non-Hormone Replacement Therapy (non-HRT)
Number of subjects: 331
Study 12014437 — intervention group
Group type: EXPERIMENTAL
Intervention: Grip strength measurement
Number of subjects: 331
Study 10080880 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO+high Fe (200 U/kg/other day of rhEPO + 12 mg/kg/day of iron)
Number of subjects: 21
Study 10080880 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO+standard Fe (200 U/kg/other day of rhEPO + 4 mg/kg/day of iron)
Number of subjects: 21
Study 10080880 — intervention group
Group type: COMPARATOR
Intervention: Standard Fe (4 mg/kg/day of iron only)
Number of subjects: 21
Study 7739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 252
Study 7739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 252
Study 7739990 — intervention group
Group type: EXPERIMENTAL
Intervention: Both genders
Number of subjects: 252
Study 2202451 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg prednisolone daily
Number of subjects: 14
Study 2202451 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg prednisolone daily
Number of subjects: 14
Study 2202451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7174801 — intervention group
Group type: EXPERIMENTAL
Intervention: Group sessions intervention
Number of subjects: 652
Study 31654779 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20μg subcutaneous daily)
Number of subjects: 1360
Study 31654779 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines/hypnotics
Number of subjects: 1360
Study 31654779 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs
Number of subjects: 1360
Study 31654779 — intervention group
Group type: COMPARATOR
Intervention: Risedronate (35mg oral weekly)
Number of subjects: 1360
Study 31010058 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat oral nutritional supplement (HFS)
Number of subjects: 21
Study 31010058 — intervention group
Group type: COMPARATOR
Intervention: Non-HFS (control group)
Number of subjects: 21
Study 28142098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinicians selecting symptoms from a predetermined criteria list
Number of subjects: 113
Study 28142098 — intervention group
Group type: COMPARATOR
Intervention: Clinicians freely listing features of the disorders based on their own mental representations
Number of subjects: 113
Study 26453327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Number of subjects: 200
Study 26453327 — intervention group
Group type: COMPARATOR
Intervention: Aerobic continuous training
Number of subjects: 200
Study 26453327 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training or aerobic continuous training
Number of subjects: 200
Study 23610112 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific adverse events (AEs) including vasomotor symptoms (VMSs)
Number of subjects: 9325
Study 23610112 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific adverse events (AEs) including musculoskeletal adverse events (MSAEs)
Number of subjects: 9325
Study 23610112 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific adverse events (AEs) including vulvovaginal symptoms (VVSs)
Number of subjects: 9325
Study 21474490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 21474490 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 30
Study 19300423 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g/day CLA with 37.5 mg/day ramipril
Number of subjects: 80
Study 19300423 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 37.5 mg/day ramipril
Number of subjects: 80
Study 17201808 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat treatment for 6 months
Number of subjects: 29
Study 17201808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 29
Study 15156547 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 252
Study 15156547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 11672759 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg intravenous acetylsalicylic acid (ASA)
Number of subjects: 19
Study 11672759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9442990 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry in hemiplegic patients
Number of subjects: 25
Study 9442990 — intervention group
Group type: COMPARATOR
Intervention: Dual-energy X-ray absorptiometry in normal subjects
Number of subjects: 25
Study 7946163 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide
Number of subjects: 61
Study 7946163 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 61
Study 3364865 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 49
Study 3364865 — intervention group
Group type: COMPARATOR
Intervention: Scalpel
Number of subjects: 49
Study 29965890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU
Number of subjects: 159
Study 29965890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 26183588 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of biopsychosocial message
Number of subjects: 281
Study 26183588 — intervention group
Group type: EXPERIMENTAL
Intervention: Not perceiving the biopsychosocial message
Number of subjects: 281
Study 26183588 — intervention group
Group type: COMPARATOR
Intervention: Physical therapists' treatment orientations or attitudes
Number of subjects: 281
Study 25424931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine recipients
Number of subjects: 5673
Study 25424931 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 5673
Study 25424931 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine recipients (large-scale cohort)
Number of subjects: 5673
Study 23512639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) alone
Number of subjects: 77
Study 23512639 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) + venlafaxine extended-release (VXR)
Number of subjects: 77
Study 23512639 — intervention group
Group type: COMPARATOR
Intervention: Lisdexamfetamine dimesylate (LDX) or LDX + venlafaxine extended-release (VXR)
Number of subjects: 77
Study 20518254 — intervention group
Group type: EXPERIMENTAL
Intervention: MAK (1.5 g/day) for 12 months
Number of subjects: 123
Study 20518254 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 123
Study 18389985 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cm limited quadriceps exposure minimally invasive surgery total knee replacement (2cm Quad MIS TKR)
Number of subjects: 40
Study 18389985 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee replacement
Number of subjects: 40
Study 15971460 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg/day
Number of subjects: 300
Study 15971460 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker (control)
Number of subjects: 300
Study 12412571 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Helicobacter pylori eradication
Number of subjects: 281
Study 12412571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 10613553 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (median sternotomy, cardiopulmonary bypass)
Number of subjects: 36
Study 10613553 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass with median sternotomy
Number of subjects: 36
Study 10613553 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral minithoracotomy and cardiopulmonary bypass
Number of subjects: 36
Study 10613553 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump procedure and lateral minithoracotomy
Number of subjects: 36
Study 8697983 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-surgery-CT
Number of subjects: 80
Study 8697983 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-RT-CT
Number of subjects: 80
Study 8697983 — intervention group
Group type: COMPARATOR
Intervention: RT-CT
Number of subjects: 80
Study 1827125 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day spironolactone
Number of subjects: 48
Study 1827125 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/day CPA
Number of subjects: 48
Study 6261782 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg oral salbutamol
Number of subjects: 25
Study 6261782 — intervention group
Group type: COMPARATOR
Intervention: No salbutamol (control)
Number of subjects: 25
Study 28441894 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sclerosis home automated tele-management system
Number of subjects: 24
Study 28441894 — intervention group
Group type: COMPARATOR
Intervention: Routine home rehabilitation (Control)
Number of subjects: 24
Study 27822319 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (800 mg DHA/day)
Number of subjects: 991
Study 27822319 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements
Number of subjects: 991
Study 27822319 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil
Number of subjects: 991
Study 24754630 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill Walking (DW) at -20%, 1.36 m/s
Number of subjects: 32
Study 24754630 — intervention group
Group type: COMPARATOR
Intervention: Level Walking at 0%
Number of subjects: 32
Study 24754630 — intervention group
Group type: COMPARATOR
Intervention: Uphill Walking at +20%
Number of subjects: 32
Study 24754630 — intervention group
Group type: COMPARATOR
Intervention: Mixed Walking at +20% and -20%
Number of subjects: 32
Study 23565744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salience target in working memory
Number of subjects: 0
Study 23565744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-salience target in working memory
Number of subjects: 0
Study 23565744 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high-salience, 'pop-out' targets
Number of subjects: 0
Study 23565744 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-based effects
Number of subjects: 0
Study 20236173 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS contralateral to symptoms
Number of subjects: 62
Study 20236173 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 Hz rTMS contralateral to symptoms
Number of subjects: 62
Study 20236173 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz rTMS ipsilateral to symptoms
Number of subjects: 62
Study 20236173 — intervention group
Group type: COMPARATOR
Intervention: 25 Hz rTMS ipsilateral to symptoms
Number of subjects: 62
Study 20236173 — intervention group
Group type: COMPARATOR
Intervention: Left side rTMS
Number of subjects: 62
Study 19049481 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (100 mg three times daily)
Number of subjects: 20
Study 19049481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20